Additionally, we continue to actively pursue in-licensing opportunities for clinical-stage assets.” About RAPT Therapeutics, Inc. RAPT Therapeutics is a clinical-stage, immunology-based therapeutics ...
The U.S. Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups, as an ...
FDA officials said an agency review of the available data found oral phenylephrine is not effective as a nasal decongestant ...
J&J is the third medtech company to gain U.S. approval for pulsed field ablation, a new atrial fibrillation treatment seeing rapid adoption.
(AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, today announced that AB-1003 (also known as LION-101) has received rare pediatric disease ...
On Friday, BTIG reaffirmed its Buy rating and $10.00 stock price target for Humacyte (NASDAQ:HUMA) following the release of a Form 483 from the FDA. The form, which details findings from facility ...
The company said it was not yet established that the vaccine had caused the safety event and it was working with the FDA to resolve the pause. "Our goal is to successfully resolve this matter and ...
New Developer Platform delivers more flexibility and control to unlock new workflows, applications, and material options. New bulk material pricing brings prices as low as $35 per liter for SLA ...
At the conclusion of the FDA’s inspection of the firm, investigators provided the firm with a Form FDA 483a FSVP Observations. Furthermore, the company’s hazard analysis did not account for ...